RAPT Therapeutics saw the highest growth of 0.99% in patent filings in June and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of RAPT Therapeutics’s patent filings and grants. Buy the databook here.
RAPT Therapeutics has been focused on protecting inventions in Israel(IL) with two publications in Q2 2024
The Israel(IL) Patent Office dominates the patent grants with nearly 67% of grants. The United States(US), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where RAPT Therapeutics is filings its patents. Among the top granted patent authorities, RAPT Therapeutics has 67% of its grants in Israel(IL) and 33% in United States(US).
Roche could be the strongest competitor for RAPT Therapeutics
Patents related to cell & gene therapy and rare diseases lead RAPT Therapeutics's portfolio
RAPT Therapeutics has the highest number of patents in cell & gene therapy followed by, rare diseases. For cell & gene therapy, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Gastric cancer related patents lead RAPT Therapeutics portfolio followed by melanoma, and thyroid cancer
RAPT Therapeutics has highest number of patents in gastric cancer followed by melanoma, thyroid cancer, lung adenocarcinoma, and squamous cell carcinoma. For gastric cancer, nearly 2% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of RAPT Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.